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educational gap, and implement and assess the effectiveness of an experiential curriculum on acute infusion reaction management.
Methods
We included current rheumatology fellows and recent graduates from five fellowship programs. Using a novel behavioral checklist we assessed fellows' performance managing an infusion reaction in a simulation, followed by a didactic focused on infusion reactions. Pre and post-surveys assessed experiences to determine relevance, as well as attitudes and knowledge.
Results
Despite ubiquitous prescribing of infusible biologic DMARDs, >50% of fellows were uncomfortable managing infusion reactions. Only 11% of fellows reported infusion reaction training during fellowship, but 56% reported managing actual patient infusion reactions. In the simulated infusion reaction, fellows managed grade 1 reactions appropriately, but grade 4 reactions poorly, meeting <50% of objectives. All fellows discontinued the infusion in the setting of anaphylaxis, but only 56% administered epinephrine. There was no difference in performance or written knowledge by training year. All fellows felt more prepared to manage infusion reactions post-curriculum and were satisfied with the experience.
Conclusion
We confirmed an education gap in rheumatology fellowship training regarding infusion reactions, both in knowledge and performance. We developed and implemented a brief experiential curriculum including simulation of a high-risk patient care scenario. This curriculum was well received and is easily exportable to other programs.
INTRODUCTION
Biologic disease-modifying anti-rheumatic drugs (DMARDs), which target disease specific pathways, are commonly prescribed to manage rheumatic diseases. All biologic DMARDS have the potential to cause serious adverse effects including injection site reactions (ISRs) and infusion reactions. Up to 30% of patients in clinical trials of injectable DMARDS This article is protected by copyright. All rights reserved.
experience ISRs (1) . Infusion reactions are also common, affecting nearly 10% of patients receiving infliximab, with an incidence of 6.1% (2) . Reported rates are as high as 45% with pegloticase in phase 3 clinical trials (3) . As learning to appropriately "prescribe, monitor and assess response to pharmacotherapy, including immunomodulatory agents" is a core competency of rheumatology fellowship training, it seems infusion therapy management would be a part of all fellowship curricula (4, 5) . However, informal surveying of rheumatology program directors from the Carolinas Fellows Collaborative (CFC) revealed no formalized curricula. To date there are no published educational curricula for rheumatology providers addressing infusion reaction management. Furthermore, there are no published studies of how often rheumatology fellows, practicing rheumatologists or physicians from other fields who prescribe infusion medications manage infusion reactions.
Based on lack of formal education about this topic, we hypothesized current rheumatology fellows' knowledge about infusion reactions would be poor. We also assumed rheumatology fellows and recent graduates would agree infusion reaction management should be taught because of the high potential for morbidity to patients. To address this potential education gap, we developed and implemented a brief and intensive educational curriculum that included a needs assessment survey, a practical simulation with immediate corrective feedback and an instructive didactic to summarize the topic. We then collected feedback about this experiential curriculum. Finally, we assessed practice patterns with infusible DMARDs and experiences managing infusion reactions.
MATERIALS AND METHODS
The Duke University Institutional Review Board determined this study exempt from review.
Study population. We included current rheumatology fellows and recent (2015) (2016) graduates from five programs: Duke University, Wake Forest University, the University of North Carolina at Chapel Hill, Medical University of South Carolina and Massachusetts General Hospital. These fellows attended the annual CFC Winter Conference at Duke in 2017, during which one half-day is dedicated to performance assessment and feedback through a multiple station objective structured clinical examination (OSCE). This article is protected by copyright. All rights reserved. Attitudes, Comfort, and Experience with Infusion Reactions. The attitude of nearly all fellows both before and after this curriculum, and of all graduates, was that the topic of acute infusion reactions is important to learn (Table 1) . Most (15 [83%]) fellows and graduates (9 [90%] ) disagreed that acute infusion reaction management was "the job of the infusion service provider and not my responsibility." All graduates recommended current fellows be taught how to manage acute infusion reactions. Reasons given included: "We are usually responsible for managing infusion reactions," "Applicable to any fellow regardless of future career path," "We prescribe them, we should be able to manage the reaction," and "Knowledge of management is imperative if you are prescribing these drugs, especially in your clinic site, I feel my rheumatology training was lacking in this aspect." Pre-curriculum, 11 (61%) fellows agreed their "knowledge is poor in the management of acute infusion
Pre-curriculum
Regarding comfort, 8 (44%) current fellows reported feeling comfortable managing infusion reactions; of the 7 fellows physically involved in such a situation, 3 (43%) were uncomfortable with their ability to manage the reaction. Surveyed post-curriculum, all fellows answered they felt comfortable managing an infusion reaction. All 10 graduates reported feeling comfortable with their ability to manage a patient with an acute infusion reaction. All respondents reported a preference for prescribing subcutaneous biologic DMARDS over IV therapies ( Table 2) . Two (11%) fellows on the pre-and 5 (24%) on the post-survey, along with 2 (20%) graduates, agreed this preference was due to concerns about their ability to manage an acute infusion reaction.
Practice patterns among fellows and graduates differ. While all respondents reported prescribing intravenous (IV) medications to treat rheumatic diseases, graduates (nearly all in private practice) primarily infuse DMARDs within the immediate clinic area, while fellows use a variety of infusion services (supplemental). Over half of graduates reported <10% of their patients were receiving infusion medications, while more than half of current fellows estimated 10-25% of their patients were receiving infusible medications. Though both groups prescribed many different medications, all current fellows and only half of graduates prescribed cyclophosphamide.
Regarding experience with infusion reactions (Table 2) This article is protected by copyright. All rights reserved.
In the pre-didactic knowledge assessment (supplemental), current fellows demonstrated a generally poor understanding of NCI-CTCAE infusion reaction grading through their inability to correctly match signs and symptoms to the correct reaction grade. However, when given an infusion reaction grade and asked to determine if they would 1) continue, 2) decrease the rate or 3) stop the infusion, most fellows chose the correct management option, except in grade 3 in which only 55% chose correctly (discontinue the infusion). There was no This article is protected by copyright. All rights reserved.
DISCUSSION
We created and tested an easily transferrable educational curriculum on acute infusion reactions. We confirmed a gap in training, with minimal formal education about acute infusion reactions prior to or during fellowship. Nonetheless, most current fellows had been called to manage infusion reactions, and nearly half reported feeling uncomfortable with their ability to manage these patients. Poor OSCE performance confirmed that fellows should feel uncomfortable managing infusion reactions, since their average score was only 4.3/10 in simulated management of a grade 4 infusion reaction. These findings are concerning, since most graduates who enter private practice can expect an office-based infusion center. Of interest, while this sample of recent graduates reported comfort managing infusion reactions, all reported a preference for subcutaneous DMARDs and nearly 20% related this preference to their discomfort managing infusion reactions.
Certainly, though, the ultimate decision on biologic formulation is not made in isolation, considering factors including disease-activity, cost/insurance coverage, patient preference, convenience, co-morbid risk factors and current/prior medications. This brief experiential curriculum is grounded in assumptions of several adult-learning theories. As per Knowles' assumptions, we established curriculum relevance, setting the stage prior to delivery through a survey requiring fellows to reflect on their comfort with the topic and a brief knowledge assessment to highlight their own learning needs. Fellows were notified they would face a simulated infusion reaction situation, giving them opportunity to pre-read about infusion reactions. The simulated event took place during an annual conference, when fellows were "in the mode" of learning, consistent with the Theory of Margin. Finally, experiential learning through an OSCE followed by a didactic with highThis article is protected by copyright. All rights reserved.
quality information for managing a future, similar situation, is consistent with Jarvis' theory of transformational learning (13) .
We identified differences between written knowledge and clinical performance. While most fellows correctly matched infusion reaction grade with appropriate management decisions, grade 4 reaction management was poor on the OSCE. All fellows appropriately recognized the need to discontinue an infusion for a severe infusion reaction, but only 56% recommended epinephrine for anaphylaxis, suggesting either limited anaphylaxis recognition or inadequate management knowledge. Prior studies have shown poor recognition and management of anaphylaxis in other specialties (14, 15) . We presume fellows had not previously learned about the NCI-CTCAE grading system for infusion reactions, although their gestalt regarding whether to discontinue an infusion was generally correct. Learning the NCI-CTCAE grading system provides a foundation for gauging the severity of and appropriately managing acute infusion reactions, promoting favorable outcomes.
Limitations of this study include the use of not yet validated tools to assess knowledge and OSCE performance (none currently exist) and small sample size. Additionally, survey and knowledge assessments were anonymous, preventing correlation of confidence with competence for individual fellows. Since this was the initial implementation of this curriculum, determining improved knowledge during fellowship was not possible.
Graduates reported a higher rate of training/education during fellowship compared to current fellows. We are not aware of any substantial curricular changes within the 5 fellowship programs and attribute this difference to the possibility of recall bias, sampling This article is protected by copyright. All rights reserved. Recording the didactic session will make it usable by other programs.
In summary, we successfully developed and implemented an acute infusion reaction educational curriculum for rheumatology fellows, meeting an important educational need for safe future practice. All participants felt this topic was important, some graduates commented they wished their training programs had provided this education. As a rheumatologist, management of both rheumatic disease and medication related adverse effects are critical to patient care. This curriculum can easily be implemented by any training program, with the ability to simulate a high-risk clinical scenario by phone. With the exploding use of targeted biologic infusion therapies in multiple fields, this curriculum can be widely adapted for multiple specialties. Table 2 *"Residency lecture," "from senior resident" †Institutional GME training, "advice from 2 attendings" -reported little to moderate amount of influence ⱡ6/7 reported 2 or more times (85%); 1/7 reported more than 10 incidents §None resulted in death ¶3/18 (16.7%) had concerns about their ability to manage an infusion reaction affecting preference #2/6 during fellowship orientation, 3/6 general academic lecture, 1/6 dedicated conference course, 2/6 other -"from rheumatology attending I worked with" and "preceptor bringing me along when called to manage an infusion reaction" **5/5 reported between 2-10 incidents per graduate † †2/10 had concerns about their ability to manage an infusion reaction affecting preference Table 3 *Most common rate reduction was by 50%
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This article is protected by copyright. All rights reserved. As a rheumatologist, I should be able to manage a patient having an acute infusion reaction from a DMARD.
18 (100) 21 (100) 9ⱡ (100) The management of an acute infusion reaction is the job of the infusion service provider and not my responsibility. 
Knowl edge
My knowledge is poor in the management of acute infusion reactions. 11 (61.1) n/a n/a My knowledge about acute infusion reactions is improved. n/a 21 (100) n/a I am more aware of IV medication related adverse effects. n/a 21 (100) n/a
This article is protected by copyright. All rights reserved. n/a n/a Infusion reaction training/education during fellowship 2 † (11.1) 16 (88.9) 6# (60) 4 (40) Current practice, were you required to complete any training for infusion reaction management n/a n/a -10 (100)
Prior experience working in an infusion clinic with primary role of administering medication -18 (100) n/a n/a During fellowship ever been physically involved in managing an acute infusion reaction 7ⱡ (38.9) 11 (61.1) n/a n/a During fellowship ever been paged regarding a patient having an acute infusion reaction 10 (55.6) 8 (44.4) n/a n/a During fellowship, did you ever assess or manage a patient having an acute infusion reaction (either in person or by phone) n/a n/a 4 (40) 6 (60)
Since graduation from fellowship, has one of your patients had an acute infusion reaction n/a n/a 2 (22.2) 7 (77.8) Since graduation, have you had to assess or manage a patient having an acute infusion reaction (either in person or by phone) n/a n/a 5** (50) 5 (50)
Change a patient's therapy because of an infusion reaction 11 (61.1) 7 (38.9) n/a n/a Has a patient you were treating sustained direct harm, to include death, related to an infusion therapy being prescribed 3 § (16.7) 15 (83.3) n/a n/a Relevance During fellowship, have you prescribed IV medications for the direct treatment of a rheumatic disease 18 (100) -n/a n/a
Since graduation from fellowship, have you prescribed IV medications for direct treatment of a rheumatic disease n/a n/a 9 (90) 1 (10) Given the option, do you prefer to prescribe subcutaneous over IV medications 18 ¶ (100) -10 † † (100) -Do you recommend fellows be taught how to manage acute infusion reactions n/a n/a 10 (100) -This article is protected by copyright. All rights reserved. 
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